Sab biotherapeutics provides company update for full year 2022

Sioux falls, s.d., march 31, 2023 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), (sab), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (higg) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the full year ended december 31, 2022, and provided a company update.
SABS Ratings Summary
SABS Quant Ranking